Efficacy and safety of the weight-loss drug rimonabant

The Lancet

Volumn 371, Issue 9612, 2008, Pages 555-

  Després, Jean Pierre ^a   Van Gaal, Luc ^b   Pi Sunyer, Xavier ^c   Scheen, André ^d  

^a LAVAL UNIVERSITY   (Canada)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT; ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MENTAL DISEASE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SUICIDAL BEHAVIOR; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; MAJOR DEPRESSION; NOTE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; SUICIDE;

ANTI-OBESITY AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; OBESITY; PATIENT SELECTION; PIPERIDINES; PYRAZOLES; SUICIDE;

EID: 38949204040     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60261-5     Document Type: Letter

References (3)

1. Christensen R., Kristensen P., Bartels E., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
2. Klein D. The flawed basis for FDA post-marketing decisions: the example of anti-depressants and children. Neuropsychopharmacology 31 (2006) 689-699
3. European Medicines Agency. Acomplia: summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-PI-en.pdf (accessed Nov 21, 2007).